Treatment with 10 μM MK-2206, an Akt inhibitor widely used in the clinical trials for cancer indicated a significant decrease in the expression of phosphorylated Akt, Phosphorylated GSK-3α/β, claudin-5, ZO-1 and ZO-2 protein levels compared to DMSO-treated controls in HLECs (Fig. 5a–d). The gene discussed is TJP2; the disease is cancer.